Evaluation of retroperitoneal and pelvic lymph node metastases with MRI and MR lymphangiography

Abdominal Imaging

Volumn 28, Issue 2, 2003, Pages 155-163

  Bellin, M F ^a   Lebleu, L ^b   Meric, J B ^a  

^a HÔPITAL PAUL BROUSSE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Lymphatic system, magnetic resonance; Lymphatic system, neoplasms; Magnetic resonance, contrast enhancement; Magnetic resonance, metastases; Pelvic neoplasms, magnetic resonance; Retroperitoneal neoplasms, magnetic resonance

Indexed keywords

CONTRAST MEDIUM; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ASPIRATION BIOPSY; B LYMPHOCYTE; BIOACCUMULATION; BONE MARROW; CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CAPILLARY PERMEABILITY; CIRCULATION TIME; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG TOLERABILITY; DRUG UPTAKE; GERMINAL CENTER; HEART ARRHYTHMIA; HISTIOCYTE; HUMAN; HYPOVOLEMIA; INJECTION; KIDNEY; KIDNEY PELVIS CARCINOMA; LIVER; LOW BACK PAIN; LYMPH FOLLICLE; LYMPH NODE; LYMPHOGRAPHY; MACROPHAGE; MEDICAL ASSESSMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; RASH; RETICULUM CELL; RETROPERITONEAL CANCER; REVIEW; SIDE EFFECT; SPLEEN; T LYMPHOCYTE;

CONTRAST MEDIA; FEMALE; HUMANS; IRON; LYMPH NODES; LYMPHATIC METASTASIS; MAGNETIC RESONANCE ANGIOGRAPHY; MAGNETIC RESONANCE IMAGING; MALE; OXIDES; PELVIC NEOPLASMS; RETROPERITONEAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 0345237914     PISSN: 09428925     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00261-001-0182-9     Document Type: Review

References (35)

1. Weissleder R, Elizondo G, Wittenberg J, et al. Ultrasmall superparamagnetic iron oxide: characterization of a new class of contrast agents for MR imaging. Radiology 1990;175:489-493
2. Lee AS, Weissleder R, Brady TJ, et al. Lymph nodes: microstructural anatomy at MR imaging. Radiology 1991;178:519-522
3. Guimaraes R, Clement O, Bittoun J, et al. MR lymphography with superparamagnetic iron nanoparticles in rats: pathologic basis for contrast enhancement. AJR 1994;162:201-207
4. Tanoura T, Bernas M, Darkazanli A, et al. MR lymphography with iron oxide compound AMI-227: studies in ferrets with filariasis. AJR 1992;159:875-881
5. Anzai Y, Blackwell KE, Hirschowitz SL, et al. Initial clinical experience with Dextran-coated superparamagnetic iron oxide for detection of lymph-node metastases in patients with head and neck cancer. Radiology 1994;192:709-715
6. Anzai Y, McLachlan S, Morris M, et al. Dextran-coated superparamagnetic iron oxide: an MR contrast agent for assessing lymphnodes in the head and neck. Am J Neuroradiol 1994;15:87-94
7. Bellin MF, Roy C, Kinkel K, et al. Lymph-node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles. Initial clinical experience. Radiology 1998;207:799-808
8. Weissleder R, Heautot JF, Schaffer BK, et al. MR lymphography: study of a high-efficiency lymphotropic agent. Radiology 1994;191: 225-230
9. Harisinghani MG, Saini S, Weissleder R, et al. MR lymphography using ultrasmall superparamagnetic iron oxide in patients with primary abdominal and pelvic malignancies: radiographic-pathologic correlation. AJR 1999;172:1347-1351
10. Oyen RH, van Poppel HP, Ameye FE, et al. Lymph-node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients. Radiology 1994;190:315-322
11. Dooms GC, Hricak H, Crooks LE, et al. Magnetic resonance imaging of the lymph-nodes: comparison with CT. Radiology 1984; 153:719-728
12. Lee JKT, Heiken JP, Ling D, et al. Magnetic resonance imaging of abdominal and pelvic lymphadenopathy. Radiology 1984;153:181-188
13. Kim SH, Choi BI, Lee HP, et al. Uterine cervical carcinoma: evaluation of pelvic lymph-node metastasis with MR imaging. Radiology 1994;190:807-811
14. 1-weighted magnetization-prepared-rapid gradient-echo sequence. AJR 1996;167:1503-1507
15. Davis GL. Sensitivity of frozen section examination of pelvic lymph-node for metastatic prostate carcinoma. Cancer 1995;76: 661-666
16. Hricak H, Dooms GC, Jeffrey RB, et al. Prostatic carcinoma: staging by clinical assessment, CT, and MR imaging. Radiology 1987;162:331-336
17. Dooms GC, Hricak H, Mosely MR, et al. Characterization of lymphadenopathy by magnetic relaxation times: preliminary results. Radiology 1985;155:691-697
18. McClennan BL, Deyoe LA. The imaging evaluation of renal cell carcinoma: diagnosis and staging. Radiol Clin North Am 1994;32: 55-69
19. Platt JF, Bree RL, Schwab RE. The accuracy of CT in the staging of carcinoma of the prostate. AJR 1987;149:315-318
20. Kim SH, Choi BI, Lee HP, et al. Uterine cervical carcinoma: comparison of CT and MR findings. Radiology 1990:175:45-51
21. Chagnon S, Cochand-Priollet B, Gzaeil M, et al. Pelvic cancers: staging of 139 cases with lymphography and fine-needle aspiration biopsy. Radiology 1989;173:103-106
22. Nagano T, Nakai Y, Taniguchi F, et al. Diagnosis of paraaortic and pelvic lymph-node metastasis of gynecologic malignant tumors by ultrasound-guided percutaneous fine-needle aspiration biopsy. Cancer 1991;68:2571-2574
23. McLachlan S, Morris MR, Lucas MA, et al. Phase I clinical evaluation of a new iron oxide MR contrast agent. J Magn Reson Imaging 1994;4:301-307
24. Hudgins PA, Anzai Y, Christino A, et al. Dextran-coated superparamagnetic iron oxide MR contrast agent (Combidex) for imaging cervical lymph-nodes: optimal dose, time of imaging, and pulse sequence [abstract]. Proceedings of the American Society of Neuroradiology. Oak Brook, IL: American Society of Neuroradiology, 1996:247
25. Bellin MF, Zaim S, Auberton E, et al. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology 1994;193:657-663
26. Gretz J, Anderson A, Shaw S. Cords, channels, corridors and conduits: critical architectural elements facilitating interactions in the lymph-node cortex. Immunol Rev 1997; 156:11-24
27. Bengele HH, Palmacci S, Rogers J, et al. Biodistribution of an ultrasmall superparamagnetic iron oxide colloid, BMS 18549, by different routes of administration. J Magn Reson Imaging 1994;12: 433-442
28. Chambon C, Clement O, Le Blanche A, et al. Superparamagnetic iron oxides as positive MR contrast agents: in vitro and in vivo evidence. J Magn Reson Imaging 1993;11:509-519
29. Anzai Y, Prince MR. Iron oxide-enhanced MR lymphography: the evaluation of cervical lymph-node metastases in head and neck cancer. J Magn Reson Imaging 1997;7:75-81
30. Gerlowski LE, Jain RK. Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986;31:288-305
31. Harisinghani MG, Saini S, Slater GJ, et al. MR imaging of pelvic lymph-nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (Combidex): preliminary observations. J Magn Reson Imaging 1997;7:161-163
32. Anzai Y, Som PH, Maravilla KR, et al. Ultrasmall superparamagnetic iron oxide contrast agent for head and neck cancer [abstract]. Proceedings of the Radiological Society of North America. Chicago, IL: Radiological Society of North America, 1999:277
33. Taupitz M, Hamm BK, Barentsz JO, et al. Sinerem®-enhanced MR imaging compared to plain MR imaging in evaluating lymph-node metastases from urologic and gynecologic cancers [abstract]. Proceedings of the Radiological Society of North America. Chicago, IL: Radiological Society of North America, 1999:387
34. Taupitz M, Wallis F, Heywang-Koebrunner SH, et al. Axillary lymph-node MR imaging with Sinerem® in patients with suspected breast cancer [abstract]. Proceedings of the Radiological Society of North America. Chicago, IL: Radiological Society of North America, 1999:387
35. Bellin MF, Beigelman C, Precetti-Morel S. Iron oxide-enhanced MR lymphography: initial experience. Eur J Radiol 2000;34:257-264